

REMARKS

Claims 1, 24, 34, 44 and 54 have been amended to recite that the folate receptor α comprises at least one or more agonist or antagonist agent of at least one steroid receptor. Claim 7 has been canceled.

Claims 1 – 6, 8 – 11, 16, 26, 36, 46 and 56 have been amended to remove the objections thereto and the rejections thereof under 35 U.S.C. §112.

These amendments do not contain new matter. Accordingly, Applicants respectfully ask that the amendments be entered.

The objections to claims 10 and 11 because of multiple dependency has been corrected. Claims 10 and 11 now only depend on claim 1.

The objections to claims 8, 9 and 44 have been corrected. The informalities have been corrected. Claim 9 now depends on claim 1 instead of claim 8.

Applicants respectfully traverse the rejection of claims 1-9, 12, 13, 16, 17, 26, 27, 36, 37, 46, 47, 56 and 57 under 35 U.S.C. §112, second paragraph.

Claim 1 now recites only a method of treating.

Claims 3 – 5 now recite proper processing steps. Claim 9 now depends on claim 1 instead of claim 8.

Claims 6, 16, 26, 36, 46 and 56 have been amended to provide proper antecedent basis.

Accordingly, Applicants respectfully ask that this rejection be withdrawn.

Applicants respectfully traverse the rejection of claims 1, 2, 6-8, 12-16, 24-26, 34-36, 44-46 and 54-56 under 35 U.S.C. §102(b) over Taylor (Taylor, C.W., et al.. Breast Cancer Research and Treatment, 42:7-14, 1997) as evidenced by Kelley (Kelley, K.M.M. et al. Cancer Research, 63: 2820-2828, 2003, June).

Applicants claims patentably distinguish over the cited references in the recitation of the folate receptor α comprising at least one or more agonist or antagonist agent of at least one steroid receptor.

Nowhere do the cited references disclose or suggest this. This subject matter is not anticipated nor suggested by the prior art. Nor has this subject matter been rejected under 35 U.S.C. §102 or 35 U.S.C. §103.

Accordingly, Applicants respectfully ask that this rejection be withdrawn.

Applicants respectfully traverse the rejection of claims 1- 3, 6-8, 12-16, 34-36, 44-46 and 54-56 under 35 U.S.C. §102(b) over Tamargo (Tamargo, R.J., et al. J. Neurosurg. 74(6):956-961, 1991; abstract only) as evidenced by Kelley (Kelley, K.M.M. et al. Cancer Research, 63: 2820-2828, 2003, June).

Applicants claims patentably distinguish over the cited references in the recitation of the folate receptor α comprising at least one or more agonist agent of at least one steroid receptor.

Nowhere do the cited references disclose or suggest this. This subject matter is not anticipated nor suggested by the prior art. Nor has this subject matter

been rejected under 35 U.S.C. §102 over 35 U.S.C. §103.

Accordingly, Applicants respectfully ask that this rejection be withdrawn.

Applicants respectfully ask that claims 1-6, 8-17, 24-27, 34-37, 44-47 and 54-57 be allowed and passed to issue.

Respectfully submitted,

EMCH, SCHAFFER, SCHAUB
& PORCELLO CO., L.P.A.



Patrick P. Pacella
Reg. No.: 25,463

P.O. Box 916
Toledo, Ohio 43697
Ph: (419) 243-1294
Fax (419) 243-8502